COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA

被引：0
|
作者：
Mihajlovic, J. [1 ]
Pechlivanoglou, P. [1 ]
Sabo, A. [2 ]
Tomic, Z. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Univ Novi Sad, Fac Med, Novi Sad 21000, Serbia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2141
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
  • [2] ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND LINE TREATMENT IN METASTATIC RENAL CANCER IN MEXICO
    Nevarez-Sida, A.
    Fuentes-Alburo, A.
    VALUE IN HEALTH, 2012, 15 (04) : A221 - A221
  • [3] Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium
    Van, Nooten F.
    Dewilde, S.
    Van Belle, S.
    Marbaix, S.
    VALUE IN HEALTH, 2007, 10 (06) : A329 - A329
  • [4] CLINICAL EFFECTIVENESS AND COST-EFFECTIVE SECOND-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA
    Romero, M.
    Diaz, E.
    Malagon, J.
    VALUE IN HEALTH, 2011, 14 (07) : A543 - A543
  • [5] Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
    Pitt, M.
    Crathorne, L.
    Moxham, T.
    Bond, M.
    Hyde, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 41 - 46
  • [6] Second-line everolimus treatment in advanced renal-cell cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2012, 13 (06): : E235 - E235
  • [7] The use of everolimus in the treatment of the second line in a patient with clear cell renal cancer
    Monka, Pawel
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 : C32 - C33
  • [8] ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN GREECE
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Koutsoukos, K.
    Bournakis, E.
    Boutis, A.
    Syrios, J.
    Tzovaras, A.
    Michailidi, C.
    Kalogeropoulou, M.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [9] COST UTILITY ANA LYSIS OF EVEROLIMUS IN THE TREATMENT OF METASTATIC RENAL CELL CANCER IN THE NETHERLANDS
    Mihajlovic, J.
    Minovic, I
    Bruinsma, A.
    Postma, M. J.
    VALUE IN HEALTH, 2013, 16 (07) : A416 - A416
  • [10] COST OF CARE WITH EVEROLIMUS VERSUS AXITINIB FOR SECOND-LINE METASTATIC RENAL CELL CARCINOMA PATIENTS IN CANADA
    Perrin, A.
    Chua, A.
    Wang, X.
    Hurry, M.
    VALUE IN HEALTH, 2013, 16 (07) : A402 - A402
12345